Inactive Instrument

Biovica International AB Share Price Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
- SEK - Intraday chart for Biovica International AB

Financials

Sales 2024 * 10M 950K 74.56M Sales 2025 * 116M 11.02M 865M Capitalization 202M 19.17M 1.5B
Net income 2024 * -115M -10.93M -857M Net income 2025 * -60M -5.7M -447M EV / Sales 2024 * 12.8 x
Net cash position 2024 * 73.52M 6.99M 548M Net cash position 2025 * 45.95M 4.37M 343M EV / Sales 2025 * 1.34 x
P/E ratio 2024 *
-0.32 x
P/E ratio 2025 *
-0.84 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.54%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 54 31/12/09
Director of Finance/CFO 59 31/12/22
Chief Tech/Sci/R&D Officer 45 31/12/21
Members of the board TitleAgeSince
Chairman 64 19/03/19
Director/Board Member 61 31/12/19
Director/Board Member 68 31/12/15
More insiders
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.
More about the company